KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Return on Assets (2016 - 2025)

Historic Return on Assets for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to 0.01%.

  • Alnylam Pharmaceuticals' Return on Assets rose 900.0% to 0.01% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.01%, marking a year-over-year increase of 900.0%. This contributed to the annual value of 0.07% for FY2024, which is 500.0% up from last year.
  • According to the latest figures from Q3 2025, Alnylam Pharmaceuticals' Return on Assets is 0.01%, which was up 900.0% from 0.07% recorded in Q2 2025.
  • Alnylam Pharmaceuticals' 5-year Return on Assets high stood at 0.01% for Q3 2025, and its period low was 0.34% during Q3 2022.
  • Moreover, its 5-year median value for Return on Assets was 0.24% (2021), whereas its average is 0.18%.
  • In the last 5 years, Alnylam Pharmaceuticals' Return on Assets plummeted by -1000bps in 2022 and then soared by 2900bps in 2024.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Return on Assets stood at 0.24% in 2021, then crashed by -33bps to 0.32% in 2022, then skyrocketed by 64bps to 0.11% in 2023, then skyrocketed by 43bps to 0.07% in 2024, then surged by 114bps to 0.01% in 2025.
  • Its Return on Assets stands at 0.01% for Q3 2025, versus 0.07% for Q2 2025 and 0.06% for Q1 2025.